ASCO 2022: Advances in CLL/SLL

PCE

内容由Practicing Clinicians Exchange提供。所有播客内容（包括剧集、图形和播客描述）均由 Practicing Clinicians Exchange 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

2+ y ago 37:17

MP3•单集首页

In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:

Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLL
Updated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLL
Progression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs
Obinutuzumab + Chlorambucil as first-line therapy in CLL
Assessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLL

Presenter

John M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado

Moderator

Amy Esposito, FNP-C
Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado

86集单集

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Practicing Clinicians Exchange #Apps For Education #Np Education #Credit #App Medicine #Pa Education #Np Medicine #Pa Medicine #CE #Apps #CME